Skip to main content

Table 4 Survival of patients according to neutrophil-lymphocyte ratio (NLR) before both neoadjuvant chemotherapy and surgery

From: Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

NLR changed by chemotherapya Number PFS OS
Median survival, months P value Median survival, months P value
NLR >2.5 NLR >2.5 13 10   16  
NLR ≤2.5 NLR ≤2.5 15 49 <0.001 42 0.015
NLR >2.5 NLR ≤2.5 11 35   60  
NLR ≤2.5 NLR ≤2.5 15 49 0.648 42 0.869
NLR >2.5 NLR ≤2.5 11 35   60  
NLR >2.5 NLR >2.5 13 10 0.003 16 0.042
  1. NLR, Neutrophil to lymphocyte ratio.
  2. aChange between pre-chemotherapy and pre-operative NLR.